Reuters logo
BRIEF-Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD
September 27, 2017 / 12:17 PM / 23 days ago

BRIEF-Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD

Sept 27 (Reuters) - Aduro Biotech Inc

* Aduro Biotech announces first patient dosed in Phase 1 clinical trial of personalized immunotherapy pLADD based on proprietary neoantigen technology

* Aduro Biotech Inc - ‍trial is seeking to enroll approximately 10 patients with metastatic colorectal cancer that is MSS​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below